{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:40:08Z","timestamp":1793090408095,"version":"4.5.0"},"reference-count":241,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:00:00Z","timestamp":1610236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702802"],"award-info":[{"award-number":["81702802"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003213","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","award":["KM201810005032"],"award-info":[{"award-number":["KM201810005032"]}],"id":[{"id":"10.13039\/501100003213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003213","name":"Beijing Municipal Education Commission","doi-asserted-by":"publisher","award":["KM201810005005"],"award-info":[{"award-number":["KM201810005005"]}],"id":[{"id":"10.13039\/501100003213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10555-020-09952-0","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T02:07:58Z","timestamp":1610244478000},"page":"245-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression"],"prefix":"10.1007","volume":"40","author":[{"given":"Aamir Ali","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakhawat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,10]]},"reference":[{"key":"9952_CR1","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a Cancer Journal for Clinicians, 69, 7\u201334.2.","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"9952_CR2","unstructured":"Street W. Cancer Facts & Figures 2019. American Cancer Society: Atlanta, GA, USA. 2019. (Accessed on 19-11-2019)."},{"issue":"11","key":"9952_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74(11), 2913\u20132921.","journal-title":"Cancer Research"},{"issue":"2","key":"9952_CR4","first-page":"74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians, 55(2), 74\u2013108.","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"2","key":"9952_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1758834014564775","volume":"7","author":"A Teague","year":"2015","unstructured":"Teague, A., Lim, K. H., & Wang-Gillam, A. (2015). Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology., 7(2), 68\u201384.","journal-title":"Therapeutic Advances in Medical Oncology."},{"issue":"4","key":"9952_CR6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00104-012-2455-y","volume":"84","author":"H Niess","year":"2013","unstructured":"Niess, H., Kleespies, A., Andrassy, J., Pratschke, S., Angele, M. K., Guba, M., Jauch, K. W., & Bruns, C. J. (2013). Pancreatic cancer in the elderly: guidelines and individualized therapy. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen., 84(4), 291\u2013295.","journal-title":"Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen."},{"issue":"4","key":"9952_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein, P. E., & Olive, K. P. (2013). Pancreatic cancer: why is it so hard to treat? Therapeutic Advances in Gastroenterology, 6(4), 321\u2013337.","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"12","key":"9952_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., & Falconi, M. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England Journal of Medicine, 350(12), 1200\u20131210.","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"9952_CR9","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1093\/annonc\/mdr541","volume":"23","author":"C Bosetti","year":"2011","unstructured":"Bosetti, C., Lucenteforte, E., Silverman, D. T., Petersen, G., Bracci, P. M., Ji, B. T., Negri, E., Li, D., Risch, H. A., Olson, S. H., & Gallinger, S. (2011). Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Annals of Oncology, 23(7), 1880\u20131888.","journal-title":"Annals of Oncology"},{"issue":"7","key":"9952_CR10","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","volume":"64","author":"AP Klein","year":"2004","unstructured":"Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., Griffin, C., Cameron, J. L., Yeo, C. J., Kern, S., & Hruban, R. H. (2004). Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Research, 64(7), 2634\u20132638.","journal-title":"Cancer Research"},{"issue":"1","key":"9952_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","volume":"15","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo, M., Cascinu, S., Kleeff, J., Labianca, R., L\u00f6hr, J. M., Neoptolemos, J., Real, F. X., Van Laethem, J. L., & Heinemann, V. (2015). Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology., 15(1), 8\u201318.","journal-title":"Pancreatology."},{"key":"9952_CR12","unstructured":"Stewart BW, Wild CP (2019). World cancer report, 2014. Public Health."},{"issue":"8","key":"9952_CR13","first-page":"626","volume":"89","author":"MS De La Cruz","year":"2014","unstructured":"De La Cruz, M. S., Young, A. P., & Ruffin, M. T. (2014). Diagnosis and management of pancreatic cancer. American Family Physician, 89(8), 626\u2013632.","journal-title":"American Family Physician"},{"key":"9952_CR14","unstructured":"Street W. Cancer Facts & Figures 2019. American Cancer Society: Atlanta, GA, USA. 2019. https:\/\/www.cancer.org\/cancer\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html. (Accessed on Nov 22, 2019)."},{"issue":"1","key":"9952_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World Journal of Oncology., 10(1), 10.","journal-title":"World Journal of Oncology."},{"issue":"1","key":"9952_CR16","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a Cancer Journal for Clinicians, 66(1), 7\u201330.","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"28","key":"9952_CR17","first-page":"9354","volume":"20","author":"S Mohammed","year":"2014","unstructured":"Mohammed, S., George Van Buren, I. I., & Fisher, W. E. (2014). Pancreatic cancer: advances in treatment. World journal of gastroenterology: WJG, 20(28), 9354.","journal-title":"World journal of gastroenterology: WJG"},{"key":"9952_CR18","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.ejca.2014.06.021","volume":"50","author":"J Haqq","year":"2014","unstructured":"Haqq, J., Howells, L. M., Garcea, G., Metcalfe, M. S., Steward, W. P., & Dennison, A. R. (2014). Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. European Journal of Cancer, 50, 2570\u20132582.","journal-title":"European Journal of Cancer"},{"key":"9952_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/j.gastro.2010.05.084","volume":"139","author":"N Ikenaga","year":"2010","unstructured":"Ikenaga, N., Ohuchida, K., Mizumoto, K., Cui, L., Kayashima, T., Morimatsu, K., et al. (2010). CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology, 139, 1041\u20131051.","journal-title":"Gastroenterology"},{"key":"9952_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.4161\/cc.19679","volume":"11","author":"E Lonardo","year":"2012","unstructured":"Lonardo, E., Frias-Aldeguer, J., Hermann, P. C., & Heeschen, C. (2012). Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle, 11, 1282\u20131290.","journal-title":"Cell Cycle"},{"key":"9952_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., et al. (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 62, 112\u2013120.","journal-title":"Gut"},{"key":"9952_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simson, T., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with diminished survival. Cancer Cell, 25, 719\u2013734.","journal-title":"Cancer Cell"},{"key":"9952_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., et al. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 25, 735\u2013747.","journal-title":"Cancer Cell"},{"key":"9952_CR24","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., et al. (2018). Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology, 155, 1999\u20132013.","journal-title":"Gastroenterology"},{"key":"9952_CR25","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G., Hoadley, K. A., et al. (2015). Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 47, 1168\u20131178.","journal-title":"Nature Genetics"},{"issue":"1","key":"9952_CR26","first-page":"10","volume":"57","author":"C Ye","year":"2019","unstructured":"Ye, C., Zheng, L., & Yuan, C. H. (2019). Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Zhonghua wai ke za zhi [Chinese Journal of Surgery]., 57(1), 10\u201315.","journal-title":"Zhonghua wai ke za zhi [Chinese Journal of Surgery]."},{"key":"9952_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.12.012","volume":"417","author":"K Banerjee","year":"2018","unstructured":"Banerjee, K., Kumar, S., Ross, K. A., et al. (2018). Emerging trends in the immunotherapy of pancreatic cancer. Cancer Letters, 417, 35\u201346.","journal-title":"Cancer Letters"},{"key":"9952_CR28","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. The New England Journal of Medicine, 377, 2500\u20132501.","journal-title":"The New England Journal of Medicine"},{"key":"9952_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nm.4082","volume":"22","author":"H Laklai","year":"2016","unstructured":"Laklai, H., Miroshnikova, Y. A., Pickup, M. W., et al. (2016). Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine, 22, 497.","journal-title":"Nature Medicine"},{"key":"9952_CR30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3114","volume-title":"The pancreas cancer microenvironment","author":"C Feig","year":"2012","unstructured":"Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012). The pancreas cancer microenvironment. AACR: In."},{"key":"9952_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00424-017-1968-0","volume":"469","author":"PE Ferdek","year":"2017","unstructured":"Ferdek, P. E., & Jakubowska, M. A. (2017). Biology of pancreatic stellate cellsdmore than just pancreatic cancer. Pfl\u00fcgers Archiv - European Journal of Physiology, 469, 1039\u20131050.","journal-title":"Pfl\u00fcgers Archiv - European Journal of Physiology"},{"key":"9952_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fphys.2012.00344","volume":"3","author":"M Apte","year":"2012","unstructured":"Apte, M., Pirola, R., & Wilson, J. (2012). Pancreatic stellate cells: a starring role in normal and diseased pancreas. Frontiers in Physiology, 3, 344.","journal-title":"Frontiers in Physiology"},{"key":"9952_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang, H., Hegde, S., & DeNardo, D. G. (2017). Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunology, Immunotherapy, 66, 1037\u20131048.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"9952_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.canlet.2015.10.035","volume":"381","author":"SP Pothula","year":"2016","unstructured":"Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2016). Key role of pancreatic stellate cells in pancreatic cancer. Cancer Letters, 381, 194\u2013200.","journal-title":"Cancer Letters"},{"key":"9952_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-017-0448-5","volume":"10","author":"D Von Ahrens","year":"2017","unstructured":"Von Ahrens, D., Bhagat, T. D., Nagrath, D., Maitra, A., & Verma, A. (2017). The role of stromal cancer-associated fibroblasts in pancreatic cancer. Journal of Hematology & Oncology, 10, 76.","journal-title":"Journal of Hematology & Oncology"},{"key":"9952_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund, D., Handly-Santana, A., Biffi, G., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of Experimental Medicine, 214, 579\u2013596.","journal-title":"The Journal of Experimental Medicine"},{"key":"9952_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell, 25, 719\u2013734.","journal-title":"Cancer Cell"},{"key":"9952_CR38","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015). Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. Journal of Clinical Investigation, 125, 3365\u20133376.","journal-title":"Journal of Clinical Investigation"},{"key":"9952_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka, M. R., Mitchem, J. B., Belt, B. A., et al. (2012). Pancreatic adenocarcinoma induces bone marrow mobilization of myeloidderived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy, 61, 1373\u20131385.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"9952_CR40","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","volume":"63","author":"IM Stromnes","year":"2014","unstructured":"Stromnes, I. M., Brockenbrough, J. S., Izeradjene, K., et al. (2014). Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut., 63, 1769\u20131781.","journal-title":"Gut."},{"key":"9952_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","volume":"74","author":"G Liu","year":"2014","unstructured":"Liu, G., Bi, Y., Shen, B., et al. (2014). SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1aedependent glycolysis. Cancer Research, 74, 727\u2013737.","journal-title":"Cancer Research"},{"key":"9952_CR42","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.CIR-16-0322","volume":"5","author":"IM Stromnes","year":"2017","unstructured":"Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017). T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunology Research, 5, 978\u2013991.","journal-title":"Cancer Immunology Research"},{"issue":"31","key":"9952_CR43","doi-asserted-by":"publisher","first-page":"10778","DOI":"10.3748\/wjg.v20.i31.10778","volume":"20","author":"P Ghiorzo","year":"2014","unstructured":"Ghiorzo, P. (2014). Genetic predisposition to pancreatic cancer. World Journal of Gastroenterology, 20(31), 10778\u201310789.","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"9952_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/PAP.0b013e31817bf57d","volume":"15","author":"C Shi","year":"2008","unstructured":"Shi, C., Daniels, J. A., & Hruban, R. H. (2008). Molecular characterization of pancreatic neoplasms. Advances in Anatomic Pathology, 15(4), 185\u2013195.","journal-title":"Advances in Anatomic Pathology"},{"issue":"9791","key":"9952_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. Lancet., 378(9791), 607\u2013620.","journal-title":"Lancet."},{"issue":"6","key":"9952_CR46","doi-asserted-by":"publisher","first-page":"485491","DOI":"10.1097\/PPO.0b013e318278c4a6","volume":"18","author":"S Solomon","year":"2012","unstructured":"Solomon, S., Das, S., Brand, R., & Whitcomb, D. C. (2012). Inherited pancreatic cancer syndromes. Cancer Journal, 18(6), 485491.","journal-title":"Cancer Journal"},{"issue":"3","key":"9952_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","volume":"95","author":"SA Hahn","year":"2003","unstructured":"Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., & Campra, D. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. Journal of the National Cancer Institute, 95(3), 214\u2013221.","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"9952_CR48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/1055-9965.EPI-06-0783","volume":"16","author":"FJ Couch","year":"2007","unstructured":"Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., De Andrade, M., Goggins, M., Rothenmund, H., Gallinger, S., Klein, A., Petersen, G. M., & Hruban, R. H. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiology and Prevention Biomarkers., 16(2), 342\u2013346.","journal-title":"Cancer Epidemiology and Prevention Biomarkers."},{"issue":"13","key":"9952_CR49","first-page":"3789","volume":"62","author":"KM Murphy","year":"2002","unstructured":"Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., Hruban, R. H., & Kern, S. E. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Research, 62(13), 3789\u20133793.","journal-title":"Cancer Research"},{"issue":"5924","key":"9952_CR50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","volume":"324","author":"S Jones","year":"2009","unstructured":"Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C., Palmisano, E., Brune, K., Jaffee, E. M., & Iacobuzio-Donahue, C. A. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science., 324(5924), 217.","journal-title":"Science."},{"issue":"3","key":"9952_CR51","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2009.06.055","volume":"137","author":"MD Tischkowitz","year":"2009","unstructured":"Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., & Foulkes, W. D. (2009). Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology., 137(3), 1183\u20131186.","journal-title":"Gastroenterology."},{"issue":"5","key":"9952_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1399-0004.2010.01425.x","volume":"78","author":"EP Slater","year":"2010","unstructured":"Slater, E. P., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J. P., Greenhalf, W., & Bartsch, D. K. (2010). PALB2 mutations in European familial pancreatic cancer families. Clinical Genetics, 78(5), 490\u2013494.","journal-title":"Clinical Genetics"},{"key":"9952_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0039-6060(98)70114-X","volume":"124","author":"RF Hwang","year":"1998","unstructured":"Hwang, R. F., Gordon, E. M., Anderson, W. F., & Parekh, D. (1998). Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery, 124, 143\u2013150.","journal-title":"Surgery"},{"key":"9952_CR54","first-page":"3126","volume":"57","author":"M Schutte","year":"1997","unstructured":"Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., et al. (1997). Abrogation of the RB\/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57, 3126\u20133130.","journal-title":"Cancer Research"},{"issue":"14","key":"9952_CR55","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Eshleman, J. R., & Goggins, M. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research, 15(14), 4674\u20134679.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"9952_CR56","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-11-0269","volume":"10","author":"ST Kim","year":"2011","unstructured":"Kim, S. T., Lim, D. H., Jang, K. T., Lim, T., Lee, J., Choi, Y. L., Jang, H. L., Yi, J. H., Baek, K. K., Park, S. H., & Park, Y. S. (2011). Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Molecular Cancer Therapeutics, 10(10), 1993\u20131999.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9952_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1042\/bj20031886","volume":"379","author":"K De Bosscher","year":"2004","unstructured":"De Bosscher, K., Hill, C. S., & Nicolas, F. J. (2004). Molecular and functional consequences of SMAD4 c-terminal missense mutations in colorectal tumour cells. The Biochemical Journal, 379, 209\u2013216.","journal-title":"The Biochemical Journal"},{"key":"9952_CR58","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Eshleman, J. R., et al. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research, 15, 4674\u20134679.","journal-title":"Clinical Cancer Research"},{"key":"9952_CR59","first-page":"3126","volume":"57","author":"M Schutte","year":"1997","unstructured":"Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., et al. (1997). Abrogation of the RB\/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57, 3126\u20133130.","journal-title":"Cancer Research"},{"key":"9952_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1245\/s10434-008-0220-8","volume":"16","author":"J Chen","year":"2009","unstructured":"Chen, J., Li, D., Killary, A. M., Sen, S., Amos, C. I., Evans, D. B., Abbruzzese, J. L., & Frazier, M. L. (2009). Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Annals of Surgical Oncology, 16, 431\u2013439.","journal-title":"Annals of Surgical Oncology"},{"key":"9952_CR61","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0039-6060(98)70114-X","volume":"124","author":"RF Hwang","year":"1998","unstructured":"Hwang, R. F., Gordon, E. M., Anderson, W. F., & Parekh, D. (1998). Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery, 124, 143\u2013150.","journal-title":"Surgery"},{"key":"9952_CR62","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.256.5058.827","volume":"256","author":"SE Kern","year":"1992","unstructured":"Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science, 256, 827\u2013830.","journal-title":"Science"},{"key":"9952_CR63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","volume":"91","author":"S Bamford","year":"2004","unstructured":"Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004). Thecosmic (catalogue of somatic mutations in cancer) database and website. British Journal of Cancer, 91, 355\u2013358.","journal-title":"British Journal of Cancer"},{"key":"9952_CR64","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-11-0269","volume":"10","author":"ST Kim","year":"2011","unstructured":"Kim, S. T., Lim, D. H., Jang, K. T., Lim, T., Lee, J., Choi, Y. L., Jang, H. L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011). Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Molecular Cancer Therapeutics, 10, 1993\u20131999.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9952_CR65","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1947601911411084","volume":"2","author":"E Fernandez-Medarde","year":"2011","unstructured":"Fernandez-Medarde, E., & Santos. (2011). Ras in cancer and developmental diseases. Genes & Cancer, 2, 344\u2013358.","journal-title":"Genes & Cancer"},{"key":"9952_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web. Nature Reviews. Cancer, 11, 761\u2013774.","journal-title":"Nature Reviews. Cancer"},{"key":"9952_CR67","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-08-2753","volume":"15","author":"ECS Tites","year":"2009","unstructured":"Tites, E. C. S., & Chandran, K. S. R. (2009). A systems perspective of ras signaling in cancer. Clinical Cancer Research, 15, 1510\u20131513.","journal-title":"Clinical Cancer Research"},{"key":"9952_CR68","doi-asserted-by":"publisher","first-page":"D945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., Teague, J. W., Campbell, P. J., Stratton, M. R., & Futreal, P. A. (2011). COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research, 39, D945\u2013D950.","journal-title":"Nucleic Acids Research"},{"issue":"5897","key":"9952_CR69","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S., Zhang, X., Parsons, D. W., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science., 321(5897), 1801\u20131806.","journal-title":"Science."},{"issue":"2","key":"9952_CR70","first-page":"545","volume":"143","author":"RH Hruban","year":"1993","unstructured":"Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., et al. (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. The American Journal of Pathology, 143(2), 545\u2013554.","journal-title":"The American Journal of Pathology"},{"key":"9952_CR71","first-page":"3568","volume":"54","author":"SA Caldas","year":"1994","unstructured":"Caldas, S. A., Hahn, R. H., Hruban, M. S., & Redston, C. J. (1994). Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Research, 54, 3568\u20133573.","journal-title":"Cancer Research"},{"key":"9952_CR72","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1136\/gut.2005.083063","volume":"55","author":"J Kim","year":"2006","unstructured":"Kim, J., Reber, H. A., Dry, S. M., Elashoff, D., Chen, S. L., Umetani, N., Kitago, M., Hines, O. J., Kazanjian, K. K., Hiramatsu, S., Bilchik, A. J., Yong, S., Shoup, M., & Hoon, D. S. (2006). Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut, 55, 1598\u20131605.","journal-title":"Gut"},{"key":"9952_CR73","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L","volume":"89","author":"A Kawesha","year":"2000","unstructured":"Kawesha, A., Ghaneh, P., Andren-Sandberg, A., Ograed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N., & Neoptolemos, J. P. (2000). K-ras oncogene subtype mutations are associated with survival but not expression of p53 p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 89, 469\u2013474.","journal-title":"International Journal of Cancer"},{"key":"9952_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"CR Ferrone","year":"2013","unstructured":"RM, Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., De Pinho, R. A., Cantley, L. C., & Kimmelman, A. C. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 496, 101\u2013105.","journal-title":"Nature"},{"key":"9952_CR75","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L","volume":"89","author":"A Kawesha","year":"2000","unstructured":"Kawesha, A., Ghaneh, P., Andren-Sandberg, A., Ograed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N., & Neoptolemos, J. P. (2000). K-ras oncogene subtype mutations are associated with survival but not expression of p53 p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 89, 469\u2013474.","journal-title":"International Journal of Cancer"},{"key":"9952_CR76","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00428-006-0191-8","volume":"448","author":"H Immervoll","year":"2006","unstructured":"Immervoll, H., Hoem, D., Kugarajh, K., Steine, S. J., & Molven, A. (2006). Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Archiv, 448, 788\u2013796.","journal-title":"Virchows Archiv"},{"key":"9952_CR77","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ejso.2010.05.014","volume":"36","author":"H Chen","year":"2010","unstructured":"Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010). K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. European Journal of Surgical Oncology, 36, 657\u2013662.","journal-title":"European Journal of Surgical Oncology"},{"key":"9952_CR78","doi-asserted-by":"publisher","first-page":"251686571982834","DOI":"10.1177\/2516865719828348","volume":"12","author":"J Reza","year":"2019","unstructured":"Reza, J., Almodovar, A. J., Srivastava, M., Veldhuis, P. P., Patel, S., Fanaian, N. I., Zhu, X., Litherland, S. A., & Arnoletti, J. P. (2019). K-RAS mutant gene found in pancreatic juice activated chromatin from peri-ampullary adenocarcinomas. Epigenetics Insights., 12, 2516865719828348.","journal-title":"Epigenetics Insights."},{"issue":"1","key":"9952_CR79","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40880-019-0386-4","volume":"39","author":"C Glorieux","year":"2019","unstructured":"Glorieux, C., & Huang, P. (2019). Regulation of CD137 expression through K-Ras signalling in pancreatic cancer cells. Cancer Communications, 39(1), 41.","journal-title":"Cancer Communications"},{"issue":"2","key":"9952_CR80","first-page":"2141","volume":"17","author":"N Nishizawa","year":"2019","unstructured":"Nishizawa, N., Kumamoto, Y., Katoh, H., Ushiku, H., Yokoi, K., Tanaka, T., Ishii, S., Igarashi, K., Tajima, H., Kaizu, T., & Yoshida, T. (2019). Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a K-ras gene mutation in pancreatic ductal adenocarcinoma. Oncology Letters, 17(2), 2141\u20132150.","journal-title":"Oncology Letters"},{"key":"9952_CR81","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","volume":"93","author":"AA Adjei","year":"2001","unstructured":"Adjei, A. A. (2001). Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute, 93, 1062\u20131074.","journal-title":"Journal of the National Cancer Institute"},{"key":"9952_CR82","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1158\/1078-0432.CCR-04-0248","volume":"10","author":"NE Martin","year":"2004","unstructured":"Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., Pramanik, B., Tepper, J., Tanaka, W. K., Morrison, B., Deutsch, P., Gupta, A. K., Muschel, R. J., McKenna, W. G., Bernhard, E. J., & Hahn, S. M. (2004). A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clinical Cancer Research, 10, 5447\u20135454.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9952_CR83","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13148-019-0681-6","volume":"11","author":"MW Chao","year":"2019","unstructured":"Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M., & Pan, S. L. (2019). Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clinical Epigenetics, 11(1), 85.","journal-title":"Clinical Epigenetics"},{"issue":"30","key":"9952_CR84","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1038\/s41388-019-0849-8","volume":"38","author":"P Dent","year":"2019","unstructured":"Dent, P., Booth, L., Roberts, J. L., Liu, J., Poklepovic, A., Lalani, A. S., Tuveson, D., Martinez, J., & Hancock, J. F. (2019). Neratinib inhibits Hippo\/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene., 38(30), 5890\u20135904.","journal-title":"Oncogene."},{"key":"9952_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature., 358, 15\u201316.","journal-title":"Nature."},{"issue":"5","key":"9952_CR86","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1073\/pnas.78.5.2932","volume":"78","author":"G Jay","year":"1981","unstructured":"Jay, G., Khoury, G., DeLeo, A. B., Dippold, W. G., & Old, L. J. (1981). p53 transformation-related protein: detection of an associated phosphotransferase activity. Proceedings of the National Academy of Sciences, 78(5), 2932\u20132936.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"9952_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/sj.cdd.4401183","volume":"10","author":"M Oren","year":"2003","unstructured":"Oren, M. (2003). Decision making by p53: life, death and cancer. Cell Death and Differentiation, 10(4), 431.","journal-title":"Cell Death and Differentiation"},{"issue":"6810","key":"9952_CR88","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature., 408(6810), 307.","journal-title":"Nature."},{"issue":"1","key":"9952_CR89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ng0492-45","volume":"1","author":"WS El-Deiry","year":"1992","unstructured":"El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992). Definition of a consensus binding site for p53. Nature Genetics, 1(1), 45.","journal-title":"Nature Genetics"},{"issue":"1","key":"9952_CR90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molcel.2012.01.020","volume":"46","author":"M Li","year":"2012","unstructured":"Li, M., He, Y., Dubois, W., Wu, X., Shi, J., & Huang, J. (2012). Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Molecular Cell, 46(1), 30\u201342.","journal-title":"Molecular Cell"},{"issue":"22","key":"9952_CR91","first-page":"5187","volume":"55","author":"T Waldman","year":"1995","unstructured":"Waldman, T., Kinzler, K. W., & Vogelstein, B. (1995). p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Research, 55(22), 5187\u20135190.","journal-title":"Cancer Research"},{"issue":"6648","key":"9952_CR92","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/38525","volume":"389","author":"K Polyak","year":"1997","unstructured":"Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature., 389(6648), 300.","journal-title":"Nature."},{"issue":"6366","key":"9952_CR93","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/356215a0","volume":"356","author":"LA Donehower","year":"1992","unstructured":"Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery Jr., C. A., Butel, J. S., & Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature., 356(6366), 215.","journal-title":"Nature."},{"issue":"8","key":"9952_CR94","first-page":"1503","volume":"7","author":"B Ruggeri","year":"1992","unstructured":"Ruggeri, B., Zhang, S., Caamano, J., et al. (1992). Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor suppressor genes. Oncogene, 7(8), 1503\u20131511.","journal-title":"Oncogene"},{"issue":"34","key":"9952_CR95","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1038\/sj.onc.1204621","volume":"20","author":"JM Birch","year":"2001","unstructured":"Birch, J. M., Alston, R. D., McNally, R., et al. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20(34), 4621\u20134628.","journal-title":"Oncogene"},{"issue":"3","key":"9952_CR96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3835(93)90168-9","volume":"69","author":"G Casey","year":"1993","unstructured":"Casey, G., Yamanaka, Y., Friess, H., et al. (1993). p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters, 69(3), 151\u2013160.","journal-title":"Cancer Letters"},{"issue":"6","key":"9952_CR97","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/ajcp\/101.6.684","volume":"101","author":"JA DiGiuseppe","year":"1994","unstructured":"DiGiuseppe, J. A., Hruban, R. H., Goodman, S. N., Polak, M., Van Den Berg, F. M., Allison, D. C., Cameron, J. L., Johan, A., & Offerhaus, G. (1994). Overexpression of p53 protein in adenocarcinoma of the pancreas. American Journal of Clinical Pathology, 101(6), 684\u2013688.","journal-title":"American Journal of Clinical Pathology"},{"issue":"11","key":"9952_CR98","first-page":"3025","volume":"54","author":"MS Redston","year":"1994","unstructured":"Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., Da Costa, L., Yeo, C. J., & Kern, S. E. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Research, 54(11), 3025\u20133033.","journal-title":"Cancer Research"},{"issue":"3","key":"9952_CR99","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3835(93)90168-9","volume":"69","author":"G Casey","year":"1993","unstructured":"Casey, G., Yamanaka, Y., Friess, H., Kobrin, M. S., Lopez, M. E., Buchler, M., Beger, H. G., & Korc, M. (1993). p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Letters, 69(3), 151\u2013160.","journal-title":"Cancer Letters"},{"issue":"5","key":"9952_CR100","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10637-014-0090-9","volume":"32","author":"P Izetti","year":"2014","unstructured":"Izetti, P., Hautefeuille, A., Abujamra, A. L., et al. (2014). PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investigational New Drugs, 32(5), 783\u2013794.","journal-title":"Investigational New Drugs"},{"issue":"3","key":"9952_CR101","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/156800910791190229","volume":"10","author":"AS Azmi","year":"2010","unstructured":"Azmi, A. S., Philip, P. A., Wang, Z., et al. (2010). Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Current Cancer Drug Targets, 10(3), 319.","journal-title":"Current Cancer Drug Targets"},{"issue":"4","key":"9952_CR102","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ccell.2017.09.007","volume":"32","author":"SS Mello","year":"2017","unstructured":"Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., & Chang, D. T. (2017). A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer. Cancer Cell, 32(4), 460\u2013473.","journal-title":"Cancer Cell"},{"key":"9952_CR103","doi-asserted-by":"publisher","first-page":"112078","DOI":"10.1016\/j.phytochem.2019.112078","volume":"167","author":"CR Delma","year":"2019","unstructured":"Delma, C. R., Thirugnanasambandan, S., Srinivasan, G. P., Raviprakash, N., Manna, S. K., Natarajan, M., & Aravindan, N. (2019). Fucoidan from marine brown algae attenuates pancreatic cancer progression by regulating p53\u2013NF\u03baB crosstalk. Phytochemistry., 167, 112078.","journal-title":"Phytochemistry."},{"issue":"2","key":"9952_CR104","first-page":"390","volume":"9","author":"J Cheng","year":"2019","unstructured":"Cheng, J., Okolotowicz, K. J., Ryan, D., Mose, E., Lowy, A. M., & Cashman, J. R. (2019). Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. American Journal of Cancer Research, 9(2), 390.","journal-title":"American Journal of Cancer Research"},{"issue":"1","key":"9952_CR105","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12906-019-2544-2","volume":"19","author":"J Long","year":"2019","unstructured":"Long, J., Liu, Z., & Hui, L. (2019). Anti-tumor effect and mechanistic study of elemene on pancreatic carcinoma. BMC Complementary and Alternative Medicine, 19(1), 133.","journal-title":"BMC Complementary and Alternative Medicine"},{"key":"9952_CR106","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","volume":"17","author":"FJ Stott","year":"1998","unstructured":"Stott, F. J., Bates, S., James, M. C., et al. (1998). The alternative product from the human CDKN2a locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. The EMBO Journal, 17, 5001\u20135014.","journal-title":"The EMBO Journal"},{"issue":"6456","key":"9952_CR107","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/366704a0","volume":"366","author":"M Serrano","year":"1993","unstructured":"Serrano, M., Hannon, G. J., & Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4. Nature, 366(6456), 704\u2013707.","journal-title":"Nature"},{"issue":"3","key":"9952_CR108","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1200\/JCO.1998.16.3.1197","volume":"16","author":"WH Liggett Jr","year":"1998","unstructured":"Liggett Jr., W. H., & Sidransky, D. (1998). Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology, 16(3), 1197\u20131206.","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"9952_CR109","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","volume":"17","author":"FJ Stott","year":"1998","unstructured":"Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., & Peters, G. (1998). The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. The EMBO Journal., 17(17), 5001\u20135014.","journal-title":"The EMBO Journal."},{"issue":"5","key":"9952_CR110","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/S0002-9440(10)61104-2","volume":"160","author":"N Fukushima","year":"2002","unstructured":"Fukushima, N., Sato, N., Ueki, T., Rosty, C., Walter, K. M., Wilentz, R. E., Yeo, C. J., Hruban, R. H., & Goggins, M. (2002). Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. The American Journal of Pathology., 160(5), 1573\u20131581.","journal-title":"The American Journal of Pathology."},{"issue":"4","key":"9952_CR111","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0039-6060(01)01158-8","volume":"129","author":"B Gerdes","year":"2001","unstructured":"Gerdes, B., Ramaswamy, A., Kersting, M., Ernst, M., Lang, S., Schuermann, M., Wild, A., & Bartsch, D. K. (2001). p16INK4a alterations in chronic pancreatitis\u2014indicator for high-risk lesions for pancreatic cancer. Surgery., 129(4), 490\u2013497.","journal-title":"Surgery."},{"issue":"15","key":"9952_CR112","first-page":"3126","volume":"57","author":"M Schutte","year":"1997","unstructured":"Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., & Baylin, S. B. (1997). Abrogation of the Rb\/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57(15), 3126\u20133130.","journal-title":"Cancer Research"},{"issue":"2","key":"9952_CR113","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1245\/s10434-008-0220-8","volume":"16","author":"J Chen","year":"2009","unstructured":"Chen, J., Li, D., Killary, A. M., Sen, S., Amos, C. I., Evans, D. B., Abbruzzese, J. L., & Frazier, M. L. (2009). Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Annals of Surgical Oncology, 16(2), 431.","journal-title":"Annals of Surgical Oncology"},{"issue":"1","key":"9952_CR114","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-230X-5-22","volume":"5","author":"J Attri","year":"2005","unstructured":"Attri, J., Srinivasan, R., Majumdar, S., Radotra, B. D., & Wig, J. (2005). Alterations of tumor suppressor gene p16 INK4a in pancreatic ductal carcinoma. BMC Gastroenterology, 5(1), 22.","journal-title":"BMC Gastroenterology"},{"issue":"3","key":"9952_CR115","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00006676-200410000-00004","volume":"29","author":"P Loukopoulos","year":"2004","unstructured":"Loukopoulos, P., Kanetaka, K., Takamura, M., Shibata, T., Sakamoto, M., & Hirohashi, S. (2004). Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas., 29(3), 193\u2013203.","journal-title":"Pancreas."},{"issue":"2","key":"9952_CR116","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.bjc.6600734","volume":"88","author":"B Klump","year":"2003","unstructured":"Klump, B., Hsieh, C. J., Nehls, O., Dette, S., Holzmann, K., Kiesslich, R., Jung, M., Sinn, U., Ortner, M., Porschen, R., & Gregor, M. (2003). Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. British Journal of Cancer, 88(2), 217.","journal-title":"British Journal of Cancer"},{"issue":"14","key":"9952_CR117","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1158\/0008-5472.CAN-13-2923","volume":"74","author":"AM Heilmann","year":"2014","unstructured":"Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014). CDK4\/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Research, 74(14), 3947\u20133958.","journal-title":"Cancer Research"},{"issue":"14","key":"9952_CR118","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1158\/0008-5472.CAN-13-2923","volume":"74","author":"AM Heilmann","year":"2014","unstructured":"Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014). CDK4\/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Research, 74(14), 3947\u20133958.","journal-title":"Cancer Research"},{"key":"9952_CR119","doi-asserted-by":"crossref","unstructured":"Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., & Antonelli, K. R. (2019). Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 14.","DOI":"10.1200\/PO.19.00124"},{"issue":"5247","key":"9952_CR120","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.271.5247.350","volume":"271","author":"SA Hahn","year":"1996","unstructured":"Hahn, S. A., Schutte, M., Hoque, A. S., Moskaluk, C. A., Da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., & Kern, S. E. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21. 1. Science., 271(5247), 350\u2013353.","journal-title":"Science."},{"issue":"7","key":"9952_CR121","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0092-8674(00)81296-9","volume":"85","author":"J Massagu\u00e9","year":"1996","unstructured":"Massagu\u00e9, J. (1996). TGF\u03b2 signaling: receptors, transducers, and Mad proteins. Cell., 85(7), 947\u2013950.","journal-title":"Cell."},{"issue":"1","key":"9952_CR122","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/pin.12114","volume":"64","author":"Y Saiki","year":"2014","unstructured":"Saiki, Y., & Horii, A. (2014). Molecular pathology of pancreatic cancer. Pathology International, 64(1), 10\u201319.","journal-title":"Pathology International"},{"issue":"2","key":"9952_CR123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","volume":"29","author":"R Derynck","year":"2001","unstructured":"Derynck, R., Akhurst, R. J., & Balmain, A. (2001). TGF-\u03b2 signaling in tumor suppression and cancer progression. Nature Genetics, 29(2), 117.","journal-title":"Nature Genetics"},{"issue":"6","key":"9952_CR124","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi, Y., & Massagu\u00e9, J. (2003). Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell, 113(6), 685\u2013700.","journal-title":"Cell"},{"issue":"6835","key":"9952_CR125","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342.","journal-title":"Nature"},{"issue":"5","key":"9952_CR126","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4161\/cc.8.5.7871","volume":"8","author":"J Lecanda","year":"2009","unstructured":"Lecanda, J., Ganapathy, V., D\u2019Aquino-Ardalan, C., Evans, B., Cadacio, C., Ayala, A., & Gold, L. I. (2009). TGF\u03b2 prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest. Cell Cycle, 8(5), 742\u2013756.","journal-title":"Cell Cycle"},{"issue":"2","key":"9952_CR127","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","volume":"103","author":"J Massagu\u00e9","year":"2000","unstructured":"Massagu\u00e9, J., Blain, S. W., & Lo, R. S. (2000). TGF\u03b2 signaling in growth control, cancer, and heritable disorders. Cell., 103(2), 295\u2013309.","journal-title":"Cell."},{"issue":"1","key":"9952_CR128","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1042\/bj20031886","volume":"379","author":"K De Bosscher","year":"2004","unstructured":"De Bosscher, K., Hill, C. S., & Nicol\u00e1s, F. J. (2004). Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. The Biochemical Journal, 379(1), 209\u2013216.","journal-title":"The Biochemical Journal"},{"issue":"14","key":"9952_CR129","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/1078-0432.CCR-09-0227","volume":"15","author":"A Blackford","year":"2009","unstructured":"Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Eshleman, J. R., & Goggins, M. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research, 15(14), 4674\u20134679.","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"9952_CR130","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/MPA.0b013e318247d6af","volume":"41","author":"P Singh","year":"2012","unstructured":"Singh, P., Srinivasan, R., & Wig, J. D. (2012). SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas., 41(4), 541\u2013546.","journal-title":"Pancreas."},{"key":"9952_CR131","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MPA.0000000000000760","volume":"46","author":"H Hayashi","year":"2017","unstructured":"Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017). Utility of assessing the number of mutated KRAS, CDKN2A, Tp53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas, 46, 335\u2013340.","journal-title":"Pancreas"},{"issue":"10","key":"9952_CR132","doi-asserted-by":"publisher","first-page":"16704","DOI":"10.18632\/oncotarget.14335","volume":"8","author":"JD Wang","year":"2017","unstructured":"Wang, J. D., Jin, K., Chen, X. Y., Lv, J. Q., & Ji, K. W. (2017). Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis. Oncotarget., 8(10), 16704.","journal-title":"Oncotarget."},{"issue":"4","key":"9952_CR133","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbrc.2011.02.086","volume":"406","author":"J Hao","year":"2011","unstructured":"Hao, J., Zhang, S., Zhou, Y., Liu, C., Hu, X., & Shao, C. (2011). MicroRNA 421 suppresses DPC4\/Smad4 in pancreatic cancer. Biochemical and Biophysical Research Communications, 406(4), 552\u2013557.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"13","key":"9952_CR134","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-17-3435","volume":"24","author":"F Wang","year":"2018","unstructured":"Wang, F., Xia, X., Yang, C., Shen, J., Mai, J., Kim, H. C., Kirui, D., Kang, Y. A., Fleming, J. B., Koay, E. J., & Mitra, S. (2018). SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy. Clinical Cancer Research, 24(13), 3176\u20133185.","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"9952_CR135","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/MPA.0000000000000315","volume":"44","author":"S Yamada","year":"2015","unstructured":"Yamada, S., Fujii, T., Shimoyama, Y., Kanda, M., Nakayama, G., Sugimoto, H., Koike, M., Nomoto, S., Fujiwara, M., Nakao, A., & Kodera, Y. (2015). SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas., 44(4), 660\u2013664.","journal-title":"Pancreas."},{"issue":"16","key":"9952_CR136","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012). The pancreas cancer microenvironment. Clinical Cancer Research, 18(16), 4266\u20134276.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"9952_CR137","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrc3131","volume":"11","author":"AA Bapat","year":"2011","unstructured":"Bapat, A. A., Hostetter, G., Von Hoff, D. D., & Han, H. (2011). Perineural inva-sion and associated pain in pancreatic cancer. Nature Reviews. Cancer, 11(10), 695\u2013707.","journal-title":"Nature Reviews. Cancer"},{"issue":"2","key":"9952_CR138","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000223920","volume":"9","author":"O Warburg","year":"1956","unstructured":"Warburg, O. (1956). Origin of cancer cells. Oncologia, 9(2), 75\u201383.","journal-title":"Oncologia"},{"issue":"3","key":"9952_CR139","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00534-006-1166-5","volume":"14","author":"G Feldmann","year":"2007","unstructured":"Feldmann, G., Beaty, R., Hruban, R. H., & Maitra, A. (2007). Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pan-creat Surg, 14(3), 224\u2013232.","journal-title":"J Hepatobiliary Pan-creat Surg"},{"issue":"2","key":"9952_CR140","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","volume":"39","author":"KL Bryant","year":"2014","unstructured":"Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014). KRAS: feed-ing pancreatic cancer proliferation. Trends in Biochemical Sciences, 39(2), 91\u2013100.","journal-title":"Trends in Biochemical Sciences"},{"key":"9952_CR141","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/msb.2011.56","volume":"7","author":"D Gaglio","year":"2011","unstructured":"Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011). Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Molecular Systems Biology, 7, 523.","journal-title":"Molecular Systems Biology"},{"issue":"3","key":"9952_CR142","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.mehy.2012.06.002","volume":"79","author":"P Dell\u2019 Antone","year":"2012","unstructured":"Dell\u2019 Antone, P. (2012). Energy metabolism in cancer cells: how to explain the Warburg and Crabtree effects? Medical Hypotheses, 79(3), 388\u2013392.","journal-title":"Medical Hypotheses"},{"issue":"3","key":"9952_CR143","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., Yan, H., Wang, W., Chen, S., Viale, A., Zheng, H., Paik, J. H., Lim, C., Guimaraes, A. R., Martin, E. S., Chang, J., Hezel, A. F., Perry, S. R., Hu, J., Gan, B., Xiao, Y., Asara, J. M., Weissleder, R., Wang, Y. A., Chin, L., Cantley, L. C., et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149(3), 656\u2013670.","journal-title":"Cell"},{"issue":"21","key":"9952_CR144","doi-asserted-by":"publisher","first-page":"15121","DOI":"10.1074\/jbc.M113.470047","volume":"288","author":"Z Ma","year":"2013","unstructured":"Ma, Z., Vocadlo, D. J., & Vosseller, K. (2013). Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappaB activity in pan-creatic cancer cells. The Journal of Biological Chemistry, 288(21), 15121\u201315130.","journal-title":"The Journal of Biological Chemistry"},{"issue":"19","key":"9952_CR145","first-page":"4242","volume":"57","author":"LG Boros","year":"1997","unstructured":"Boros, L. G., Puigjaner, J., Cascante, M., Lee, W. N., Brandes, J. L., Bassilian, S., Yusuf, F. I., Williams, R. D., Muscarella, P., Melvin, W. S., & Schirmer, W. J. (1997). Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Research, 57(19), 4242\u20134248.","journal-title":"Cancer Research"},{"issue":"12","key":"9952_CR146","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.bbamcr.2018.10.005","volume":"1865","author":"G Butera","year":"2018","unstructured":"Butera, G., Pacchiana, R., Mullappilly, N., Margiotta, M., Bruno, S., Conti, P., Riganti, C., & Donadelli, M. (2018). Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochimica et Biophysica Acta, Molecular Cell Research, 1865(12), 1914\u20131923.","journal-title":"Biochimica et Biophysica Acta, Molecular Cell Research"},{"issue":"2","key":"9952_CR147","doi-asserted-by":"publisher","first-page":"97422","DOI":"10.1172\/jci.insight.97422","volume":"3","author":"HK Schofield","year":"2018","unstructured":"Schofield, H. K., Zeller, J., Espinoza, C., Halbrook, C. J., Del Vecchio, A., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H. J., Yan, W., Feng, Y., Karim, S. A., Kremer, D. M., Kumar-Sinha, C., Lyssiotis, C. A., Ljungman, M., Mor-ton, J. P., Galban, S., Fearon, E. R., & Pasca di Magliano, M. (2018). Mutant p53R270H drives altered metabolism and increased invasion in pan-creatic ductal adenocarcinoma. JCI Insight, 3(2), 97422.","journal-title":"JCI Insight"},{"issue":"10","key":"9952_CR148","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1073\/pnas.1219555110","volume":"110","author":"F Guillaumond","year":"2013","unstructured":"Guillaumond, F., Leca, J., Olivares, O., Lavaut, M. N., Vidal, N., Berthezene, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., Iovanna, J. L., Tomasini, R., & Vasseur, S. (2013). Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adeno-carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 110(10), 3919\u20133924.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"9952_CR149","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.celrep.2014.11.025","volume":"9","author":"G Baek","year":"2014","unstructured":"Baek, G., Tse, Y. F., Hu, Z., Cox, D., Buboltz, N., McCue, P., Yeo, C. J., White, M. A., DeBerardinis, R. J., Knudsen, E. S., & Witkiewicz, A. K. (2014). MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Reports, 9(6), 2233\u20132249.","journal-title":"Cell Reports"},{"issue":"34","key":"9952_CR150","doi-asserted-by":"publisher","first-page":"13787","DOI":"10.1073\/pnas.1203339109","volume":"109","author":"NV Chaika","year":"2012","unstructured":"Chaika, N. V., Gebregiworgis, T., Lewallen, M. E., Purohit, V., Radhakrish-nan, P., Liu, X., Zhang, B., Mehla, K., Brown, R. B., Caffrey, T., Yu, F., Johnson, K. R., Powers, R., Hollingsworth, M. A., & Singh, P. K. (2012). MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(34), 13787\u201313792.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"16","key":"9952_CR151","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1158\/1078-0432.CCR-14-0186","volume":"20","author":"M Shi","year":"2014","unstructured":"Shi, M., Cui, J., Du, J., Wei, D., Jia, Z., Zhang, J., Zhu, Z., Gao, Y., & Xie, K. (2014). A novel KLF4\/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clinical Cancer Research, 20(16), 4370\u20134380.","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"9952_CR152","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3748\/wjg.v20.i9.2279","volume":"20","author":"J Swierczynski","year":"2014","unstructured":"Swierczynski, J., Hebanowska, A., & Sledzinski, T. (2014). Role of abnor-mal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World Journal of Gastroenterology, 20(9), 2279\u20132303.","journal-title":"World Journal of Gastroenterology"},{"issue":"4","key":"9952_CR153","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2005.09.008","volume":"8","author":"G Hatzivassiliou","year":"2005","unstructured":"Hatzivassiliou, G., Zhao, F., Bauer, D. E., Andreadis, C., Shaw, A. N., Dhanak, D., Hingorani, S. R., Tuveson, D. A., & Thompson, C. B. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8(4), 311\u2013321.","journal-title":"Cancer Cell"},{"issue":"10","key":"9952_CR154","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1111\/cas.13766","volume":"109","author":"M Takahashi","year":"2018","unstructured":"Takahashi, M., Hori, M., Ishigamori, R., Mutoh, M., Imai, T., & Nakagama, H. (2018). Fatty pancreas: a possible risk factor for pancreatic cancer in animals and humans. Cancer Science, 109(10), 3013\u20133023.","journal-title":"Cancer Science"},{"key":"9952_CR155","first-page":"18","volume":"1","author":"CH Waddington","year":"1942","unstructured":"Waddington, C. H. (1942). The epigenotype. Endeavour., 1, 18\u201320.","journal-title":"Endeavour."},{"issue":"6004","key":"9952_CR156","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1191078","volume":"330","author":"R Bonasio","year":"2010","unstructured":"Bonasio, R., Tu, S., & Reinberg, D. (2010). Molecular signals of epigenetic states. Science, 330(6004), 612\u2013616.","journal-title":"Science"},{"issue":"7","key":"9952_CR157","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.1787609","volume":"23","author":"SL Berger","year":"2009","unstructured":"Berger, S. L., Kouzarides, T., Shiekhattar, R., & Shilatifard, A. (2009). An operational definition of epigenetics. Genes & Development, 23(7), 781\u2013783.","journal-title":"Genes & Development"},{"issue":"3","key":"9952_CR158","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/890","volume":"19","author":"M Okano","year":"1998","unstructured":"Okano, M., Xie, S., & Li, E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nature Genetics, 19(3), 219\u2013220.","journal-title":"Nature Genetics"},{"issue":"9","key":"9952_CR159","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/nar\/20.9.2287","volume":"20","author":"RW Yen","year":"1992","unstructured":"Yen, R. W., Vertino, P. M., Nelkin, B. D., et al. (1992). Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Research, 20(9), 2287\u20132291.","journal-title":"Nucleic Acids Research"},{"issue":"4","key":"9952_CR160","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/cbt.9.4.10750","volume":"9","author":"A Li","year":"2010","unstructured":"Li, A., Omura, N., Hong, S. M., & Goggins, M. (2010). Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors. Cancer Biology & Therapy, 9(4), 321\u2013329.","journal-title":"Cancer Biology & Therapy"},{"issue":"8","key":"9952_CR161","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0168-9525(97)01181-5","volume":"13","author":"JA Yoder","year":"1997","unstructured":"Yoder, J. A., Walsh, C. P., & Bestor, T. H. (1997). Cytosine methylation and the ecology of intragenomic parasites. Trends in Genetics, 13(8), 335\u2013340.","journal-title":"Trends in Genetics"},{"issue":"12","key":"9952_CR162","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1158\/1078-0432.CCR-08-2784","volume":"15","author":"MT McCabe","year":"2009","unstructured":"McCabe, M. T., Brandes, J. C., & Vertino, P. M. (2009). Cancer DNA methylation: molecular mechanisms and clinical implications. Clinical Cancer Research, 15(12), 3927\u20133937.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"9952_CR163","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1073\/pnas.0510310103","volume":"103","author":"S Saxonov","year":"2006","unstructured":"Saxonov, S., Berg, P., & Brutlag, D. L. (2006). A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proceedings of the National Academy of Sciences, 103(5), 1412\u20131417.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5673","key":"9952_CR164","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/274775a0","volume":"274","author":"C Coulondre","year":"1978","unstructured":"Coulondre, C., Miller, J. H., Farabaugh, P. J., & Gilbert, W. (1978). Molecular basis of base substitution hotspots in Escherichia coli. Nature., 274(5673), 775.","journal-title":"Nature."},{"issue":"6777","key":"9952_CR165","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/35006691","volume":"404","author":"B Hendrich","year":"2000","unstructured":"Hendrich, B., Hardeland, U., Ng, H. H., Jiricny, J., & Bird, A. (2000). correction: The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature, 404(6777), 525.","journal-title":"Nature"},{"key":"9952_CR166","doi-asserted-by":"crossref","unstructured":"Walsh, C. P., & Xu, G. L. Cytosine methylation and DNA repair. InDNA Methylation: Basic Mechanisms 2006 (pp. 283-315). Springer, Berlin. Heidelberg.","DOI":"10.1007\/3-540-31390-7_11"},{"key":"9952_CR167","first-page":"207","volume":"22","author":"GA Coetzee","year":"1991","unstructured":"Coetzee, G. A., Olumi, A. F., Spruck, C. H., & Jones, P. A. (1991). 5-Methylcytosine as an endogenous mutagen in the p53 tumor suppressor gene. InPrincess Takamatsu Symposia, 22, 207\u2013219.","journal-title":"InPrincess Takamatsu Symposia"},{"issue":"suppl_1","key":"9952_CR168","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1093\/hmg\/ddi114","volume":"14","author":"HD Morgan","year":"2005","unstructured":"Morgan, H. D., Santos, F., Green, K., Dean, W., & Reik, W. (2005). Epigenetic reprogramming in mammals. Human Molecular Genetics, 14(suppl_1), R47\u2013R58.","journal-title":"Human Molecular Genetics"},{"issue":"6","key":"9952_CR169","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.cell.2011.08.042","volume":"146","author":"N Bhutani","year":"2011","unstructured":"Bhutani, N., Burns, D. M., & Blau, H. M. (2011). DNA demethylation dynamics. Cell., 146(6), 866\u2013872.","journal-title":"Cell."},{"issue":"7310","key":"9952_CR170","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito, S., D\u2019Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010). Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature., 466(7310), 1129.","journal-title":"Nature."},{"issue":"1","key":"9952_CR171","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/01.mpa.0000246665.68869.d4","volume":"34","author":"J Li","year":"2007","unstructured":"Li, J., Zhu, J., Hassan, M. M., Evans, D. B., Abbruzzese, J. L., & Li, D. (2007). K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas., 34(1), 55.","journal-title":"Pancreas."},{"key":"9952_CR172","doi-asserted-by":"publisher","first-page":"13563","DOI":"10.1038\/srep13563","volume":"5","author":"B Tang","year":"2015","unstructured":"Tang, B., Li, Y., Qi, G., Yuan, S., Wang, Z., Yu, S., Li, B., & He, S. (2015). Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer. Scientific Reports, 5, 13563.","journal-title":"Scientific Reports"},{"issue":"6","key":"9952_CR173","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1101\/gad.9.6.650","volume":"9","author":"S Matsuoka","year":"1995","unstructured":"Matsuoka, S., Edwards, M. C., Bai, C., et al. (1995). p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development, 9(6), 650\u2013662.","journal-title":"Genes & Development"},{"issue":"13","key":"9952_CR174","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1158\/1078-0432.CCR-04-2471","volume":"11","author":"N Sato","year":"2005","unstructured":"Sato, N., Matsubayashi, H., Abe, T., Fukushima, N., & Goggins, M. (2005). Epigenetic down-regulation of CDKN1C\/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clinical Cancer Research, 11(13), 4681\u20134688.","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"9952_CR175","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0968-0004(00)89005-2","volume":"20","author":"CJ Sherr","year":"1995","unstructured":"Sherr, C. J. (1995). D-type cyclins. Trends in Biochemical Sciences, 20(5), 187\u2013190.","journal-title":"Trends in Biochemical Sciences"},{"issue":"6","key":"9952_CR176","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/MCB.18.6.3163","volume":"18","author":"M Meyyappan","year":"1998","unstructured":"Meyyappan, M., Wong, H., Hull, C., & Riabowol, K. T. (1998). Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Molecular and Cellular Biology, 18(6), 3163\u20133172.","journal-title":"Molecular and Cellular Biology"},{"issue":"5","key":"9952_CR177","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0002-9440(10)61121-2","volume":"160","author":"B Terris","year":"2002","unstructured":"Terris, B., Blaveri, E., Crnogorac-Jurcevic, T., Jones, M., Missiaglia, E., Ruszniewski, P., Sauvanet, A., & Lemoine, N. R. (2002). Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. The American Journal of Pathology., 160(5), 1745\u20131754.","journal-title":"The American Journal of Pathology."},{"issue":"4","key":"9952_CR178","first-page":"1446","volume":"9","author":"H Matsubayashi","year":"2003","unstructured":"Matsubayashi, H., Sato, N., Fukushima, N., Yeo, C. J., Walter, K. M., Brune, K., Sahin, F., Hruban, R. H., & Goggins, M. (2003). Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clinical Cancer Research, 9(4), 1446\u20131452.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9952_CR179","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/01.mpa.0000246665.68869.d4","volume":"34","author":"J Li","year":"2007","unstructured":"Li, J., Zhu, J., Hassan, M. M., Evans, D. B., Abbruzzese, J. L., & Li, D. (2007). K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas., 34(1), 55.","journal-title":"Pancreas."},{"issue":"5","key":"9952_CR180","first-page":"1053","volume":"17","author":"IS Zagon","year":"2000","unstructured":"Zagon, I. S., Roesener, C. D., Verderame, M. F., Ohlsson-Wilhelm, B. M., Levin, R. J., & McLaughlin, P. J. (2000). Opioid growth factor regulates the cell cycle of human neoplasias. International Journal of Oncology, 17(5), 1053\u20131114.","journal-title":"International Journal of Oncology"},{"issue":"13","key":"9952_CR181","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/nar\/18.13.3975","volume":"18","author":"M Comb","year":"1990","unstructured":"Comb, M., & Goodman, H. M. (1990). CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Research, 18(13), 3975\u20133982.","journal-title":"Nucleic Acids Research"},{"issue":"5","key":"9952_CR182","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/S0002-9440(10)61104-2","volume":"160","author":"N Fukushima","year":"2002","unstructured":"Fukushima, N., Sato, N., Ueki, T., Rosty, C., Walter, K. M., Wilentz, R. E., Yeo, C. J., Hruban, R. H., & Goggins, M. (2002). Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. The American Journal of Pathology., 160(5), 1573\u20131581.","journal-title":"The American Journal of Pathology."},{"issue":"2","key":"9952_CR183","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0092-8674(95)90311-9","volume":"82","author":"Z Wen","year":"1995","unstructured":"Wen, Z., Zhong, Z., & Darnell Jr., J. E. (1995). Maximal activation of transcription by Statl and Stat3 requires both tyrosine and serine phosphorylation. Cell., 82(2), 241\u2013250.","journal-title":"Cell."},{"issue":"6636","key":"9952_CR184","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/43219","volume":"387","author":"T Naka","year":"1997","unstructured":"Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., & Akira, S. (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature., 387(6636), 924.","journal-title":"Nature."},{"issue":"4","key":"9952_CR185","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jjco\/hyh035","volume":"34","author":"T Komazaki","year":"2004","unstructured":"Komazaki, T., Nagai, H., Emi, M., Terada, Y., Yabe, A., Jin, E., Kawanami, O., Konishi, N., Moriyama, Y., Naka, T., & Kishimoto, T. (2004). Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK\/STAT inhibitor, in human pancreatic cancers. Japanese Journal of Clinical Oncology, 34(4), 191\u2013194.","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"9952_CR186","first-page":"158","volume":"69","author":"KM Mah","year":"2017","unstructured":"Mah, K. M., & Weiner, J. A. (2017). Regulation of Wnt signaling by protocadherins. InSeminars in Cell & Developmental Biology, 69, 158\u2013171 Academic Press.","journal-title":"InSeminars in Cell & Developmental Biology"},{"issue":"13","key":"9952_CR187","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-10-3431","volume":"17","author":"A Vincent","year":"2011","unstructured":"Vincent, A., Omura, N., Hong, S. M., Jaffe, A., Eshleman, J., & Goggins, M. (2011). Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clinical Cancer Research, 17(13), 4341\u20134354.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"9952_CR188","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12885-019-5616-2","volume":"19","author":"MC Curia","year":"2019","unstructured":"Curia, M. C., Fantini, F., Lattanzio, R., Tavano, F., Di Mola, F., Piantelli, M., Battista, P., Di Sebastiano, P., & Cama, A. (2019). High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma. BMC Cancer, 19(1), 452.","journal-title":"BMC Cancer"},{"issue":"2","key":"9952_CR189","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1006\/dbio.2000.9801","volume":"224","author":"VM Christoffels","year":"2000","unstructured":"Christoffels, V. M., Keijser, A. G., Houweling, A. C., Clout, D. E., & Moorman, A. F. (2000). Patterning the embryonic heart: identification of five mouse Iroquois homeobox genes in the developing heart. Developmental Biology, 224(2), 263\u2013274.","journal-title":"Developmental Biology"},{"key":"9952_CR190","doi-asserted-by":"crossref","unstructured":"Chakma, K., Gu, Z., Motoi, F., Unno, M., Horii, A., & Fukushige, S. (2019). DNA hypermethylation of IRX4 is a frequent event that may confer growth advantage to pancreatic cancer cells., 01, 821\u2013821.","DOI":"10.1158\/1538-7445.AM2019-821"},{"issue":"1","key":"9952_CR191","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-019-0650-0","volume":"11","author":"MA Eissa","year":"2019","unstructured":"Eissa, M. A., Lerner, L., Abdelfatah, E., Shankar, N., Canner, J. K., Hasan, N. M., Yaghoobi, V., Huang, B., Kerner, Z., Takaesu, F., & Wolfgang, C. (2019). Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics, 11(1), 59.","journal-title":"Clinical Epigenetics"},{"issue":"2","key":"9952_CR192","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/cncr.21977","volume":"107","author":"N Sato","year":"2006","unstructured":"Sato, N., Fukushima, N., Matsubayashi, H., Iacobuzio-Donahue, C. A., Yeo, C. J., & Goggins, M. (2006). Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer., 107(2), 251\u2013257.","journal-title":"Cancer."},{"issue":"7","key":"9952_CR193","first-page":"1835","volume":"60","author":"T Ueki","year":"2000","unstructured":"Ueki, T., Toyota, M., Sohn, T., Yeo, C. J., Issa, J. P., Hruban, R. H., & Goggins, M. (2000). Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Research, 60(7), 1835\u20131839.","journal-title":"Cancer Research"},{"issue":"13","key":"9952_CR194","first-page":"3735","volume":"63","author":"N Sato","year":"2003","unstructured":"Sato, N., Fukushima, N., Maitra, A., Matsubayashi, H., Yeo, C. J., Cameron, J. L., Hruban, R. H., & Goggins, M. (2003). Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Research, 63(13), 3735\u20133742.","journal-title":"Cancer Research"},{"issue":"13","key":"9952_CR195","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-09-4227","volume":"70","author":"A Li","year":"2010","unstructured":"Li, A., Omura, N., Hong, S. M., Vincent, A., Walter, K., Griffith, M., Borges, M., & Goggins, M. (2010). Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a\/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Research, 70(13), 5226\u20135237.","journal-title":"Cancer Research"},{"issue":"32","key":"9952_CR196","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1038\/sj.onc.1206807","volume":"22","author":"N Sato","year":"2003","unstructured":"Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., Hruban, R. H., & Goggins, M. (2003). SPARC\/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor\u2013stromal interactions. Oncogene., 22(32), 5021.","journal-title":"Oncogene."},{"issue":"7","key":"9952_CR197","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4161\/cbt.7.7.6208","volume":"7","author":"N Omura","year":"2008","unstructured":"Omura, N., Li, C. P., Li, A., Hong, S. M., Walter, K., Jimeno, A., Hidalgo, M., & Goggins, M. (2008). Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. Cancer Biology & Therapy, 7(7), 1146\u20131156.","journal-title":"Cancer Biology & Therapy"},{"issue":"42","key":"9952_CR198","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2016.90","volume":"35","author":"J Li","year":"2016","unstructured":"Li, J., Wu, H., Li, W., Yin, L., Guo, S., Xu, X., Ouyang, Y., Zhao, Z., Liu, S., Tian, Y., & Tian, Z. (2016). Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1\/Akt\/NF-\u03baB signaling. Oncogene., 35(42), 5501.","journal-title":"Oncogene."},{"issue":"13","key":"9952_CR199","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-10-3431","volume":"17","author":"A Vincent","year":"2011","unstructured":"Vincent, A., Omura, N., Hong, S. M., Jaffe, A., Eshleman, J., & Goggins, M. (2011). Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clinical Cancer Research, 17(13), 4341\u20134354.","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"9952_CR200","doi-asserted-by":"publisher","first-page":"e0128814","DOI":"10.1371\/journal.pone.0128814","volume":"10","author":"MJ Thompson","year":"2015","unstructured":"Thompson, M. J., Rubbi, L., Dawson, D. W., Donahue, T. R., & Pellegrini, M. (2015). Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes. PLoS One, 10(6), e0128814.","journal-title":"PLoS One"},{"key":"9952_CR201","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1093\/nar\/11.19.6883","volume":"11","author":"MA Gama-Sosa","year":"1983","unstructured":"Gama-Sosa, M. A., Slagel, V. A., Trewyn, R. W., et al. (1983). The 5- methylcytosine content of DNA from human tumors. Nucleic Acids Research, 11, 6883\u20136894.","journal-title":"Nucleic Acids Research"},{"key":"9952_CR202","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/301089a0","volume":"301","author":"AP Feinberg","year":"1983","unstructured":"Feinberg, A. P., Vogelstein, B., et al. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature., 301, 89\u201392.","journal-title":"Nature."},{"key":"9952_CR203","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1073\/pnas.0710735105","volume":"105","author":"TA Rauch","year":"2008","unstructured":"Rauch, T. A., Zhong, X., Wu, X., et al. (2008). High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 105, 252\u2013257.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9952_CR204","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","volume":"21","author":"M Ehrlich","year":"2002","unstructured":"Ehrlich, M. (2002). DNA methylation in cancer: too much, but also too little. Oncogene., 21, 5400\u20135413.","journal-title":"Oncogene."},{"issue":"2","key":"9952_CR205","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0304-3835(03)00390-2","volume":"199","author":"N Ohike","year":"2003","unstructured":"Ohike, N., Maass, N., Mundhenke, C., et al. (2003). Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Letters, 199(2), 193\u2013200.","journal-title":"Cancer Letters"},{"issue":"14","key":"9952_CR206","first-page":"4158","volume":"63","author":"N Sato","year":"2003","unstructured":"Sato, N., Maitra, A., Fukushima, N., et al. (2003). Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research, 63(14), 4158\u20134166.","journal-title":"Cancer Research"},{"issue":"3","key":"9952_CR207","doi-asserted-by":"publisher","first-page":"885","DOI":"10.18632\/aging.101785","volume":"11","author":"H Chen","year":"2019","unstructured":"Chen, H., Kong, Y., Yao, Q., Zhang, X., Fu, Y., Li, J., Liu, C., & Wang, Z. (2019). Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients. Aging (Albany NY), 11(3), 885.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"9952_CR208","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12032-010-9683-0","volume":"28","author":"Y Zhu","year":"2011","unstructured":"Zhu, Y., Zhang, J. J., Zhu, R., Zhu, Y., Liang, W. B., Gao, W. T., Yu, J. B., Xu, Z. K., & Miao, Y. (2011). The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Medical Oncology, 28(1), 175\u2013184.","journal-title":"Medical Oncology"},{"issue":"3-4","key":"9952_CR209","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbrc.2012.10.048","volume":"429","author":"H Sekine","year":"2012","unstructured":"Sekine, H., Chen, N., Sato, K., Saiki, Y., Yoshino, Y., Umetsu, Y., Jin, G., Nagase, H., Gu, Z., Fukushige, S., & Sunamura, M. (2012). S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 429(3-4), 214\u2013219.","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"9952_CR210","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrg.2016.13","volume":"17","author":"AP Feinberg","year":"2016","unstructured":"Feinberg, A. P., Koldobskiy, M. A., & G\u00f6nd\u00f6r, A. (2016). Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nature Reviews. Genetics, 17(5), 284.","journal-title":"Nature Reviews. Genetics"},{"key":"9952_CR211","doi-asserted-by":"crossref","unstructured":"Abukiwan A, Berger MR. Epigenetics: dissecting gene expression alteration in PDAC. In Advances in DNA Repair 2018 Nov 5. IntechOpen.","DOI":"10.5772\/intechopen.80585"},{"issue":"2","key":"9952_CR212","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/ijms19020459","volume":"19","author":"A Ramassone","year":"2018","unstructured":"Ramassone, A., Pagotto, S., Veronese, A., & Visone, R. (2018). Epigenetics and microRNAs in cancer. International Journal of Molecular Sciences, 19(2), 459.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"9952_CR213","first-page":"575","volume":"89","author":"E Iguchi","year":"2016","unstructured":"Iguchi, E., Safgren, S. L., Marks, D. L., Olson, R. L., & Fernandez-Zapico, M. E. (2016). Focus: epigenetics: pancreatic cancer, a mis-interpreter of the epigenetic language. The Yale Journal of Biology and Medicine., 89(4), 575.","journal-title":"The Yale Journal of Biology and Medicine."},{"issue":"2","key":"9952_CR214","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1101\/gr.119867.110","volume":"22","author":"AF Fernandez","year":"2012","unstructured":"Fernandez, A. F., Assenov, Y., Martin-Subero, J. I., Balint, B., Siebert, R., Taniguchi, H., Yamamoto, H., Hidalgo, M., Tan, A. C., Galm, O., et al. (2012). A DNA methylation fingerprint of 1628 human samples. Genome Research, 22(2), 407\u2013419.","journal-title":"Genome Research"},{"issue":"28","key":"9952_CR215","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.1703577114","volume":"114","author":"X Hao","year":"2017","unstructured":"Hao, X., Luo, H., Krawczyk, M., Wei, W., Wang, W., Wang, J., Flagg, K., Hou, J., Zhang, H., Yi, S., et al. (2017). DNA methylation markers for diagnosis and prognosis of common cancers. Proceedings of the National Academy of Sciences of the United States of America, 114(28), 7414\u20137419.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"9952_CR216","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1210\/jc.2012-3566","volume":"98","author":"S Rodr\u00edguez-Rodero","year":"2013","unstructured":"Rodr\u00edguez-Rodero, S., Fern\u00e1ndez, A. F., Fern\u00e1ndez-Morera, J. L., Castro-Santos, P., Bayon, G. F., Ferrero, C., Urdinguio, R. G., Gonzalez-Marquez, R., Suarez, C., Fern\u00e1ndez-Vega, I., & Fresno Forcelledo, M. F. (2013). DNA methylation signatures identify biologically distinct thyroid cancer subtypes. The Journal of Clinical Endocrinology & Metabolism., 98(7), 2811\u20132821.","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"issue":"10","key":"9952_CR217","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin, S. B., & Jones, P. A. (2011). A decade of exploring the cancer epigenome \u2013 biological and translational implications. Nature Reviews. Cancer, 11(10), 726\u2013734.","journal-title":"Nature Reviews. Cancer"},{"issue":"10","key":"9952_CR218","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran, S., Martinez-Cardus, A., Sayols, S., Musulen, E., Balana, C., Estival-Gonzalez, A., Moutinho, C., Heyn, H., Diaz-Lagares, A., de Moura, M. C., et al. (2016). Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. The Lancet Oncology, 17(10), 1386\u20131395.","journal-title":"The Lancet Oncology"},{"issue":"4","key":"9952_CR219","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal, R., & Gupta, S. (2012). Epigenetic modifications in cancer. Clinical Genetics, 81(4), 303\u2013311.","journal-title":"Clinical Genetics"},{"key":"9952_CR220","doi-asserted-by":"crossref","unstructured":"Hosseini A, Minucci S (2018). Alterations of histone modifications in cancer. In: Epigenetics in human disease, vol. 6. 2nd ed; p. 141\u2013217.","DOI":"10.1016\/B978-0-12-812215-0.00006-6"},{"key":"9952_CR221","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1101\/cshperspect.a019505","volume":"8","author":"SB Baylin","year":"2016","unstructured":"Baylin, S. B., & Jones, P. A. (2016). Epigenetic determinants of cancer. Cold Spring Harbor Perspectives in Biology, 8, 9.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"9952_CR222","doi-asserted-by":"crossref","unstructured":"Berdasco, M., & Esteller, M. (2018). Clinical epigenetics: seizing opportunities for translation. Nature Reviews. Genetics.","DOI":"10.1038\/s41576-018-0074-2"},{"issue":"3","key":"9952_CR223","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodriguez-Paredes","year":"2011","unstructured":"Rodriguez-Paredes, M., & Esteller, M. (2011). Cancer epigenetics reaches mainstream oncology. Nature Medicine, 17(3), 330\u2013339.","journal-title":"Nature Medicine"},{"issue":"8","key":"9952_CR224","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis, C. D., & Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. Nature Reviews. Genetics, 17(8), 487\u2013500.","journal-title":"Nature Reviews. Genetics"},{"issue":"21","key":"9952_CR225","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman, J. G., & Baylin, S. B. (2003). Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine, 349(21), 2042\u20132054.","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"9952_CR226","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii, S. S., Van Emburgh, B. O., Sankpal, U. T., Brown, K. D., & Robertson, K. D. (2008). DNA methylation inhibitor 5-Aza-2\u2032-deoxycytidine induces reversible genomewide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Molecular and Cellular Biology, 28(2), 752\u2013771.","journal-title":"Molecular and Cellular Biology"},{"issue":"5","key":"9952_CR227","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015). Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell., 162(5), 974\u2013986.","journal-title":"Cell."},{"issue":"5","key":"9952_CR228","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015). DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell., 162(5), 961\u2013973.","journal-title":"Cell."},{"issue":"2","key":"9952_CR229","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00432-015-2026-y","volume":"142","author":"K Xue","year":"2016","unstructured":"Xue, K., Gu, J. J., Zhang, Q., Mavis, C., Hernandez-Ilizaliturri, F. J., Czuczman, M. S., & Guo, Y. (2016). Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Journal of Cancer Research and Clinical Oncology, 142(2), 379\u2013387.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"1","key":"9952_CR230","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/23808993.2017.1284557","volume":"2","author":"MM Kronfol","year":"2017","unstructured":"Kronfol, M. M., Dozmorov, M. G., Huang, R., Slattum, P. W., & McClay, J. L. (2017). The role of epigenomics in personalized medicine. Expert Rev Precis Med Drug Dev., 2(1), 33\u201345.","journal-title":"Expert Rev Precis Med Drug Dev."},{"issue":"1","key":"9952_CR231","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., & Baylin, S. B. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics, 21(1), 103\u2013107.","journal-title":"Nature Genetics"},{"issue":"7","key":"9952_CR232","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011). Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery, 1(7), 598\u2013607.","journal-title":"Cancer Discovery"},{"issue":"10","key":"9952_CR233","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones, P. A., Issa, J. P., & Baylin, S. (2016). Targeting the cancer epigenome for therapy. Nature Reviews. Genetics, 17(10), 630\u2013641.","journal-title":"Nature Reviews. Genetics"},{"issue":"6","key":"9952_CR234","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ijc.21100","volume":"116","author":"M Ezzati","year":"2005","unstructured":"Ezzati, M., Henley, S. J., Lopez, A. D., & Thun, M. J. (2005). Role of smoking in global and regional cancer epidemiology: current patterns and data needs. International Journal of Cancer, 116(6), 963\u2013971.","journal-title":"International Journal of Cancer"},{"key":"9952_CR235","doi-asserted-by":"crossref","unstructured":"Jarosz, M., Seku\u0142a, W., & Rychlik, E. (2012). Influence of diet and tobacco smoking on pancreatic cancer incidence in Poland in 1960\u20132008. Gastroenterology Research and Practice, 2012.","DOI":"10.1155\/2012\/682156"},{"issue":"1","key":"9952_CR236","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12885-016-2241-1","volume":"16","author":"YT Wang","year":"2016","unstructured":"Wang, Y. T., Gou, Y. W., Jin, W. W., Xiao, M., & Fang, H. Y. (2016). Association between alcohol intake and the risk of pancreatic cancer: a dose\u2013response meta-analysis of cohort studies. BMC Cancer, 16(1), 212.","journal-title":"BMC Cancer"},{"issue":"6","key":"9952_CR237","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/ijc.25148","volume":"127","author":"EJ Jacobs","year":"2010","unstructured":"Jacobs, E. J., Chanock, S. J., Fuchs, C. S., LaCroix, A., McWilliams, R. R., Steplowski, E., Stolzenberg-Solomon, R. Z., Arslan, A. A., Bueno-de-Mesquita, H. B., Gross, M., & Helzlsouer, K. (2010). Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). International Journal of Cancer, 127(6), 1421\u20131428.","journal-title":"International Journal of Cancer"},{"issue":"4","key":"9952_CR238","first-page":"186","volume":"6","author":"SH Davoodi","year":"2013","unstructured":"Davoodi, S. H., Malek-Shahabi, T., Malekshahi-Moghadam, A., Shahbazi, R., & Esmaeili, S. (2013). Obesity as an important risk factor for certain types of cancer. Iranian Journal of Cancer Prevention., 6(4), 186.","journal-title":"Iranian Journal of Cancer Prevention."},{"issue":"4","key":"9952_CR239","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdr398","volume":"23","author":"D Aune","year":"2011","unstructured":"Aune, D., Greenwood, D. C., Chan, D. S., Vieira, R., Vieira, A. R., Navarro Rosenblatt, D. A., Cade, J. E., Burley, V. J., & Norat, T. (2011). Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose\u2013response meta-analysis of prospective studies. Annals of Oncology, 23(4), 843\u2013852.","journal-title":"Annals of Oncology"},{"issue":"1","key":"9952_CR240","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World Journal of Oncology., 10(1), 10.","journal-title":"World Journal of Oncology."},{"issue":"31","key":"9952_CR241","doi-asserted-by":"publisher","first-page":"10778","DOI":"10.3748\/wjg.v20.i31.10778","volume":"20","author":"P Ghiorzo","year":"2014","unstructured":"Ghiorzo, P. (2014). Genetic predisposition to pancreatic cancer. World Journal of Gastroenterology, 20(31), 10778.","journal-title":"World Journal of Gastroenterology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-020-09952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-020-09952-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-020-09952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T01:10:19Z","timestamp":1666833019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-020-09952-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,10]]},"references-count":241,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["9952"],"URL":"https:\/\/doi.org\/10.1007\/s10555-020-09952-0","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,10]]},"assertion":[{"value":"23 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No human participant or animal was involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participant\/animals"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}